• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤相关巨噬细胞和调节性 T 细胞在 EBV 阳性和 EBV 阴性鼻咽癌中的预后作用。

Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.

机构信息

Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

出版信息

J Clin Pathol. 2018 Mar;71(3):267-274. doi: 10.1136/jclinpath-2017-204664. Epub 2017 Sep 6.

DOI:10.1136/jclinpath-2017-204664
PMID:28877959
Abstract

AIMS

Tumour-associated macrophages (TAMs) and regulatory T cells (Tregs) form a special niche supporting tumour progression, and both correlate with worse survival in head and neck cancers. However, the prognostic role of TAM and Tregs in nasopharyngeal carcinoma (NPC) is still unknown. Therefore, we determined differences in TAMs and Tregs in different NPC subtypes, and their prognostic significance.

METHODS

Tissue of 91 NPCs was assessed for TAMs and Tregs by determination of CD68, CD163, CD206 and FOXP3 expression in the tumour microenvironment. Clinicopathological correlations were assessed using Pearson X test, Fisher's exact test, analysis of variance and Mann-Whitney U test. Survival was analysed using Kaplan-Meier curves and Cox regression.

RESULTS

CD68 and FOXP3 counts were higher in Epstein-Barr virus (EBV)-positive NPC, while CD68-/FOXP3-, CD163+/FOXP3- and CD206+/FOXP3- infiltrates were more common in EBV-negative NPC. In the whole NPC group, CD68-/FOXP3- correlated with worse overall survival (OS), and after multivariate analysis high FOXP3 count showed better OS (HR 0.352, 95% CI 0.128 to 0.968). No difference in M2 counts existed between EBV-positive and negative NPC.

CONCLUSIONS

FOXP3, a Treg marker, seems to be an independent prognostic factor for better OS in the whole NPC group. Therefore, immune-based therapies targeting Tregs should be carefully evaluated. M2 spectrum macrophages are probably more prominent in EBV-negative NPC with also functional differences compared with EBV-positive NPC.

摘要

目的

肿瘤相关巨噬细胞(TAMs)和调节性 T 细胞(Tregs)形成了一个特殊的微环境,支持肿瘤的进展,两者与头颈部癌症的生存率降低相关。然而,TAMs 和 Tregs 在鼻咽癌(NPC)中的预后作用尚不清楚。因此,我们确定了不同 NPC 亚型中 TAMs 和 Tregs 的差异及其预后意义。

方法

通过检测肿瘤微环境中 CD68、CD163、CD206 和 FOXP3 的表达,评估 91 例 NPC 组织中的 TAMs 和 Tregs。采用 Pearson X 检验、Fisher 确切检验、方差分析和 Mann-Whitney U 检验评估临床病理相关性。采用 Kaplan-Meier 曲线和 Cox 回归分析生存情况。

结果

EBV 阳性 NPC 中 CD68 和 FOXP3 计数较高,而 EBV 阴性 NPC 中 CD68-/FOXP3-、CD163+/FOXP3-和 CD206+/FOXP3-浸润更为常见。在整个 NPC 组中,CD68-/FOXP3-与总生存期(OS)较差相关,多变量分析显示 FOXP3 计数高与 OS 较好相关(HR 0.352,95%CI 0.128 至 0.968)。EBV 阳性和阴性 NPC 之间 M2 计数无差异。

结论

Treg 标志物 FOXP3 似乎是整个 NPC 组中 OS 的独立预后因素。因此,针对 Tregs 的免疫治疗方法应仔细评估。与 EBV 阳性 NPC 相比,EBV 阴性 NPC 中可能更突出 M2 谱巨噬细胞,并且具有功能差异。

相似文献

1
Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma.肿瘤相关巨噬细胞和调节性 T 细胞在 EBV 阳性和 EBV 阴性鼻咽癌中的预后作用。
J Clin Pathol. 2018 Mar;71(3):267-274. doi: 10.1136/jclinpath-2017-204664. Epub 2017 Sep 6.
2
Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma.肿瘤浸润淋巴细胞在 EBV 阳性和 EBV 阴性鼻咽癌中的预后作用。
Oral Oncol. 2017 Aug;71:16-25. doi: 10.1016/j.oraloncology.2017.05.015. Epub 2017 Jun 3.
3
M2-polarized tumour-associated macrophages in stroma correlate with poor prognosis and Epstein-Barr viral infection in nasopharyngeal carcinoma.基质中M2极化的肿瘤相关巨噬细胞与鼻咽癌的不良预后和爱泼斯坦-巴尔病毒感染相关。
Acta Otolaryngol. 2017 Aug;137(8):888-894. doi: 10.1080/00016489.2017.1296585. Epub 2017 Apr 10.
4
The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.血浆 Epstein-Barr 病毒 DNA 对鼻咽癌患者残留颈淋巴结转移的诊断和预后价值:一项回顾性研究。
Cancer Commun (Lond). 2019 Mar 29;39(1):14. doi: 10.1186/s40880-019-0357-9.
5
Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.根据爱泼斯坦-巴尔病毒状态对晚期鼻咽癌患者进行生存分析。
Oncotarget. 2016 Apr 26;7(17):24208-16. doi: 10.18632/oncotarget.8144.
6
[Correlation analysis of the Epstein-Barr virus recruited regulatory T cells in nasopharyngeal carcinoma of immune escape].[爱泼斯坦-巴尔病毒招募的调节性T细胞在鼻咽癌免疫逃逸中的相关性分析]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Sep 7;52(9):692-697. doi: 10.3760/cma.j.issn.1673-0860.2017.09.011.
7
Epstein-Barr virus-encoded RNAs as a survival predictor in nasopharyngeal carcinoma.EB 病毒编码 RNA 作为鼻咽癌的生存预测指标。
Chin Med J (Engl). 2014;127(2):294-9.
8
Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.整合模型纳入转移性区域颈淋巴结体积和治疗前血清爱泼斯坦-巴尔病毒DNA拷贝数在预测N1期鼻咽癌患者远处转移中的预后价值
Chin J Cancer. 2017 Dec 29;36(1):98. doi: 10.1186/s40880-017-0264-x.
9
Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.血浆EB病毒DNA和18F-FDG PET/CT最大标准化摄取值对鼻咽癌复发患者的不同预后价值
PLoS One. 2015 Apr 8;10(4):e0122756. doi: 10.1371/journal.pone.0122756. eCollection 2015.
10
Epstein-Barr Virus-Induced VEGF and GM-CSF Drive Nasopharyngeal Carcinoma Metastasis via Recruitment and Activation of Macrophages. Epstein-Barr 病毒诱导的 VEGF 和 GM-CSF 通过招募和激活巨噬细胞驱动鼻咽癌转移。
Cancer Res. 2017 Jul 1;77(13):3591-3604. doi: 10.1158/0008-5472.CAN-16-2706. Epub 2017 May 8.

引用本文的文献

1
Tumor-infiltrating CD4 CD25 FOXP3 Treg is associated with plasma EBV DNA and disease progression in nasopharyngeal carcinoma.肿瘤浸润性CD4 CD25 FOXP3调节性T细胞与鼻咽癌患者血浆EBV DNA及疾病进展相关。
Infect Agent Cancer. 2025 May 9;20(1):29. doi: 10.1186/s13027-025-00660-4.
2
Expression of mTOR, CD163, α-SMA, FOXp3 as survival predictors and its significance in patients with oral squamous cell carcinoma.mTOR、CD163、α-SMA、FOXp3作为生存预测指标在口腔鳞状细胞癌患者中的表达及其意义
BMC Oral Health. 2024 Dec 18;24(1):1487. doi: 10.1186/s12903-024-05245-y.
3
EBV-associated epithelial cancers cells promote vasculogenic mimicry formation via a secretory cross-talk with the immune microenvironment.
EBV 相关上皮性癌细胞通过与免疫微环境的分泌串扰促进血管生成拟态形成。
Theranostics. 2024 Aug 19;14(13):5123-5140. doi: 10.7150/thno.100171. eCollection 2024.
4
Clinical, Epidemiological, Morphological, and Immunohistochemical Aspects of Nasopharyngeal Carcinoma-4-Year Retrospective Study in the Western Part of Romania.罗马尼亚西部鼻咽癌的临床、流行病学、形态学及免疫组化特征——4年回顾性研究
Diagnostics (Basel). 2024 Mar 29;14(7):722. doi: 10.3390/diagnostics14070722.
5
The Role of Natural Killer Cells in the Tumor Immune Microenvironment of EBV-Associated Nasopharyngeal Carcinoma.自然杀伤细胞在EB病毒相关鼻咽癌肿瘤免疫微环境中的作用
Cancers (Basel). 2024 Mar 28;16(7):1312. doi: 10.3390/cancers16071312.
6
Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.鼻咽癌:肿瘤微环境对耐药性和临床结局影响的最新观点。
Mol Cancer. 2024 Jan 22;23(1):20. doi: 10.1186/s12943-023-01928-2.
7
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.鼻咽癌精准医学:过去、现在和未来展望的全面综述。
J Transl Med. 2023 Nov 6;21(1):786. doi: 10.1186/s12967-023-04673-8.
8
Nasopharynx Battlefield: Cellular Immune Responses Mediated by Midkine in Nasopharyngeal Carcinoma and COVID-19.鼻咽战场:中期因子在鼻咽癌和新冠肺炎中介导的细胞免疫反应
Cancers (Basel). 2023 Oct 4;15(19):4850. doi: 10.3390/cancers15194850.
9
Long-Term Outcomes of Nasopharyngeal Carcinoma by Epstein-Barr Virus Status in the Chinese Population: A Multicenter Investigation.中国人群中鼻咽癌患者按EB病毒状态分组的长期预后:一项多中心研究
J Clin Med. 2023 Apr 20;12(8):3005. doi: 10.3390/jcm12083005.
10
Exploring Spatial Heterogeneity of Immune Cells in Nasopharyngeal Cancer.探索鼻咽癌中免疫细胞的空间异质性。
Cancers (Basel). 2023 Apr 5;15(7):2165. doi: 10.3390/cancers15072165.